Is There a High-Risk Subgroup of Stage I Epithelial Ovarian Cancer that Is Most Likely to Benefit From 6 Versus 3 Cycles of Adjuvant Chemotherapy?
Jamie N. Bakkum-Gamez, Debra L. Richardson, Leigh G. Seamon, Giovanni D. Aletti, Cecelia A. Powless, Gary L. Keeney, David M. O'Malley, William A. Cliby
International Journal of Gynecologic Cancer Oct 2010, 20 (7) 1125-1131; DOI: 10.1111/IGC.0b013e3181efd843
